Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 5/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM6A | O15550 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022143 | 0.81 | KDM4E (0.41) | LMNAALDH1A1GSK3BKDM4EKDM6A | |
| SCHEMBL10627492 | 0.79 | ATM (0.47) | MAT2AALDH1A1GSK3BKDM4EKDM6A | |
| SCHEMBL30186358 | 0.79 | KDM4E (0.44) | LMNAALDH1A1GSK3BCA12CA9 | |
| SCHEMBL22774031 | 0.79 | GSK3B (0.38) | LMNAGSK3BKDM4EKDM6AKDM4A | |
| SCHEMBL29576495 | 0.79 | GSK3B (0.38) | LMNAGSK3BKDM4EKDM6AKDM4A | |
| Hydrochloric Acid SCHEMBL29744368 | 0.78 | GSK3B (0.37) | LMNAGSK3BKDM4EKDM6AKDM4A | |
| SCHEMBL24904310 | 0.77 | RORA (0.40) | LMNAALDH1A1CA9CA2KDM4E | |
| SCHEMBL18359174 | 0.77 | PSEN1 (0.43) | LMNAALDH1A1KDM4EKDM6AKDM4A | |
| SCHEMBL25339009 | 0.77 | KDM4E (0.38) | ALDH1A1CA2KDM4EKDM6AKDM4A | |
| SCHEMBL10375756 | 0.77 | KCNA3 (0.44) | MAT2ALMNAALDH1A1KMOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037266-A | Antibacterial chloroxoquinoline derivative | WANG ZIHOU | 2015-11-11 | — | — | CN | disclosed |
| CN-105017145-A | Chloroxoquinoline derivative with anti-tumor activity | WANG ZIHOU | 2015-11-04 | — | — | CN | disclosed |
| CN-103864681-B | Chloroxoquinoline derivatives for antibacterial use | WANG ZIHOU (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103864680-B | Chloroxoquinoline derivative with antineoplastic activity | WANG ZIHOU (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103864681-A | Chloroxoquinoline derivatives for antibacterial use | WANG ZIHOU | 2014-06-18 | — | — | CN | disclosed |
| CN-103864680-A | Chloroxoquinoline derivative with antineoplastic activity | WANG ZIHOU | 2014-06-18 | — | — | CN | disclosed |
| US-6995173-B2 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. (US) | 2005-01-13 | — | — | US | disclosed |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC | 2003-07-10 | — | — | US | disclosed |
| US-6562838-B2 | Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced | R. T. ALAMO VENTURES I, L.L.C. | 2003-05-13 | — | — | US | disclosed |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| US-4772614-A | QUINOLINOLS | THE BOOTS COMPANY (GB) | 1988-09-20 | — | — | US | disclosed |
| CN-86104611-A | The preparation method of therapeutical agent | — | 1988-01-27 | — | — | CN | disclosed |
| EP-0206616-A2 | Quinolones having antihypertensive activity | The Boots Company PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | MAT2A 239/4885NTRK1 4870/4885LMNA 1679/4885 |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | PMP22, NLN, SLC6A2 | MAT2A 851/4885NTRK1 497/4885LMNA 3541/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | MAT2A 239/4885NTRK1 4870/4885LMNA 1679/4885 |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | PMP22, NLN, SLC6A2 | MAT2A 851/4885NTRK1 497/4885LMNA 3541/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | MAT2A 1535/4885NTRK1 4312/4885LMNA 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.